Excision BioTherapeutics is a preclinical stage biotechnology company focused on the development of gene editing therapies for HIV, HPV, and other viral infections. The company was founded in 2015 by Dr. Kamel Khalili, Director of the Comprehensive NeuroAIDS Center at Temple University’s Lewis Katz School of Medicine and one of the pioneers in the field of HIV gene therapy.
As a relatively new player in this space, many investors and individuals interested in Excision BioTherapeutics have been asking whether or not it is publicly traded so that they can invest in its future success.
Currently, however, Excision BioTherapeutics is not publicly traded – meaning it does not trade on any stock exchanges such as NASDAQ or NYSE. As a private company, Excision has more freedom to focus on r&d without having to worry about satisfying shareholder expectations.
Despite its status as a privately held corporation for now, there are several reasons why investors may be interested in keeping an eye on Excision’s developments:
Firstly, the field of gene-editing therapies offers immense potential. Gene Editing could be viewed as one of those few fields where nearly-impossible disease treatments come within reach through innovations being made under this branch – making up for great investment opportunities with promising returns long-term. Even though arguably still early stages with regard to treatment plans becoming available from budding companies like Etalon Therapeutics (publicly listed), CRISPR Tx (also publicly listed), Editas Medicine (Publicly Listed), there is certainly lots going for enthusiasts looking out for something new.
Secondarily, with established players such as Vertex Pharmaceuticals investing significantly into these smaller companies who show promise along with Google Ventures investing upwards of $300 million into newer players like Verve Therapeutics also showcases investor interest & optimism towards these biotherapeutic ventures.
Lastly because Expertise: Management Matters – Led by veteran biotech executives Dan Anderson and Frances Rosario, the company has a strong management presence that likely knows exactly what excision biotherapeutics needs in order to navigate the often-choppy waters of early-stage drug development. Investors might find it beneficial to keep informed about them as they intend on investing from $10m up to £50m ($13-$64M) into these companies.
As with all private ventures in biotechnology space — there is no exact timeline when they go public or/and get acquired – however big pharma will very much want to take such impactful & juicy projects under their canopy once they see good data/successful clinical trials come out. With gene editing companies already being appealing for investment, some are bound to match expectations sooner than others which is why people are keen on getting an answer whether Excision BioTherapeutics is publicly listed yet – but looking at the current landscape and potential moving forward, there’s obviously enough interest around its trajectory thus far for prospective investors eyeing them so closely!
All said we can conclude by saying though Excision BioTherapeutics is not currently traded publicly – given gene-editing promises great potential & receives relatively large capital inflows from established players such as Vertex Pharmaceuticals therefore if successful could pave way for an IPO or potentially even spark talks of acquisition amongst industry behemoths. Nonetheless, it makes sense for enthusiasts interested in long-term investments in this ever-evolving healthcare tech landscape where newer therapies cure rather than just cater disease symptoms through chemotherapy projects like Excision BioTherapeutics feature promising outlooks and opportunities worthwhile keeping tabs on despite being unable to invest directly (At least till listed).
Excision BioTherapeutics is a biotechnology company that specializes in gene editing therapies for HIV, HPV, and other viral infections. Founded in 2015 by Dr. Kamel Khalili, the company has gained widespread attention for its innovative work in the field of HIV gene therapy.
Despite being a relatively new player, Excision BioTherapeutics has attracted considerable interest from investors and individuals interested in the potential of gene-editing therapies. However, as a private company, it does not currently trade on any stock exchange like NASDAQ or NYSE.
There are several reasons why investors and researchers should keep an eye on Excision’s developments – firstly because the field of gene-editing offers immense potential for treating previously impossible diseases using cutting-edge technology. Companies such as Etalon Therapeutics (publicly listed), CRISPR Tx (also publicly listed), Editas Medicine (Publicly Listed) have already made significant strides in this area.
Secondly, established players like Vertex Pharmaceuticals have invested significantly in smaller companies with promise along with Google Ventures investing heavily into newer start-ups like Verve Therapeutics which highlights investor interest & optimism towards these biotherapeutic ventures.
Lastly – expertise matters – Excision BioTherapeutics’ management team includes veteran biotech executives Dan Anderson and Frances Rosario who bring vast experience to navigate early-stage drug development successfully.
While there is no exact timeline when they go public or get acquired within the biotechnology space- big players within pharmaceuticals will want to take impactful projects such as those offered by Gene Editing companies under their canopy sooner than later once they see groundbreaking data/successful clinical trials emerge. Henceforth seen less commonly heard still make perfect sense would be: Given large capital inflows being directed towards emerging players such as Vertex Pharmaceuticals where professionals foresee great potential; successful projects could pave way for IPOs or even spark talks of acquisition amongst bigger industry behemoths making long-term investments worthwhile.
Overall, while Excision BioTherapeutics is currently privately held, the company’s innovative work in gene editing and strong management team make it a promising choice for investors looking to keep an eye on up-and-coming biotechnology ventures.